ERASCA INC

ERASCA stock rises 2.49% as Phase II lung‑cancer trial data sparks investor confidence, positioning the company closer to its $24.28 52‑week peak.

Explore Erasca Inc’s market outlook, clinical pipeline, and peer performance to gauge upside potential in high‑risk oncology.

Er A Sca shares slip 0.89 % as investors await next clinical data; discover how a precision‑oncology firm’s outlook and market context shape its future valuation.

ERAS stock jumps 7.34% as investors bet on Erasca’s clinical‑stage precision oncology pipeline, signaling renewed confidence in its breakthrough cancer therapies.